Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.37 |
| ▸ | CTSL | P07711 | 12/20 | 0.35 |
| ▸ | CTSB | P07858 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 6/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112618 | 0.91 | CTSS (0.37) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL21112622 | 0.91 | CTSS (0.37) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL29640198 | 0.84 | AAK1 (0.34) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL20908216 | 0.81 | MMP1 (0.36) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL29640227 | 0.81 | MMP1 (0.36) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL21149528 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL28399073 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL29640241 | 0.78 | MEN1 (0.37) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL20907560 | 0.78 | MEN1 (0.37) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL28407708 | 0.78 | MEN1 (0.37) | CTSSCTSLCTSBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111212832-B | 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors | 吉利德科学公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | CTSS 27/4885CTSL 41/4885CTSB 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.